Mark E. Robson

58.4k total citations · 10 hit papers
412 papers, 19.5k citations indexed

About

Mark E. Robson is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Mark E. Robson has authored 412 papers receiving a total of 19.5k indexed citations (citations by other indexed papers that have themselves been cited), including 222 papers in Genetics, 161 papers in Oncology and 130 papers in Cancer Research. Recurrent topics in Mark E. Robson's work include BRCA gene mutations in cancer (206 papers), Cancer Genomics and Diagnostics (91 papers) and PARP inhibition in cancer therapy (74 papers). Mark E. Robson is often cited by papers focused on BRCA gene mutations in cancer (206 papers), Cancer Genomics and Diagnostics (91 papers) and PARP inhibition in cancer therapy (74 papers). Mark E. Robson collaborates with scholars based in United States, United Kingdom and Canada. Mark E. Robson's co-authors include Kenneth Offit, Susan M. Domchek, Jaya M. Satagopan, Nadine Tung, Judy E. Garber, Larry Norton, Jeffrey N. Weitzel, Jeff Boyd, Binghe Xu and Elżbieta Senkus and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Mark E. Robson

383 papers receiving 19.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine profile →
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

2010 1.3k citations Mark E. Robson, Judy E. Garber et al. profile →
Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation

2002 891 citations Noah D. Kauff, Mark E. Robson et al. New England Journal of Medicine profile →
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

2015 579 citations Marc Tischkowitz, D. Gareth Evans et al. New England Journal of Medicine profile →
A note on competing risks in survival data analysis

2004 559 citations Mark E. Robson et al. profile →
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

2017 521 citations Mark E. Robson, Marc Ladanyi et al. profile →
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

2015 512 citations Mark E. Robson, Susan M. Domchek et al. Journal of Clinical Oncology profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Mark E. Robson, Nadine Tung et al. Annals of Oncology profile →
Genome doubling shapes the evolution and prognosis of advanced cancers

2018 343 citations Pedram Razavi, Mark E. Robson et al. profile →
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

2024 67 citations Allison W. Kurian, Payal D. Shah et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Mark E. Robson

Since Specialization

Citations

This map shows the geographic impact of Mark E. Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Robson more than expected).

Fields of papers citing papers by Mark E. Robson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Robson. The network helps show where Mark E. Robson may publish in the future.

Co-authorship network of co-authors of Mark E. Robson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Robson. A scholar is included among the top collaborators of Mark E. Robson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Robson. Mark E. Robson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review 2024 ·Critical Reviews in Oncology/Hematology ·(unknown), (unknown), Eitan Amir, (unknown), Mark E. Robson, Nour Abuhadra, Yuan Chen, Daniel Shepshelovich, Hadar Goldvaser	0
2	Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab 2024 ·npj Breast Cancer ·(unknown), Emanuela Ferraro, (unknown), Andrea V. Barrio, Daniel J. Kelly, Shanu Modi, Andrew D. Seidman, Hannah Y. Wen, Edi Brogi, Mark E. Robson, Chau T. Dang	0
3	Clinical challenges in breast care for patients with PTEN pathogenic variants: A case series and literature review 2024 ·Austin D. Williams, (unknown), (unknown), Debra A. Mangino, Mark E. Robson, Alexandra S. Heerdt, Tracy‐Ann Moo	0
4	Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing 2024 ·Annals of Oncology ·Charlie F Rowlands, (unknown), Judith Balmañà, Susan M. Domchek, D. Gareth Evans, Helen Hanson, Nicoline Hoogerbrugge, Philip James, (unknown), Mark E. Robson, Marc Tischkowitz, William D. Foulkes, Clare Turnbull	7
5	LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial 2024 ·Annals of Oncology ·Peter Schmid, Heather L. McArthur, (unknown), Baojun Xu, (unknown), (unknown), Utkan Demirci, (unknown), Jaya Ghosh, Roberto Hegg, Hiroaki Iwata, Yamil Alonso Lopez Chuken, M. Nechaeva, Mark E. Robson, Ricardo Villalobos-Valencia, Andrew Lloyd, Celina M. D’Cruz, Andrew Foxley, Y.H. Park	5
6	198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009 2024 ·ESMO Open ·Antonio Llombart‐Cussac, (unknown), Mark E. Robson, (unknown), (unknown), Eduardo Yañez Ruiz, (unknown), J.M. Walshe, Y-H Im, Svitlana Kulyk, Alexander S. Dudnichenko, (unknown), Shigehira Saji, (unknown), (unknown), Amin Haiderali, (unknown), Allison Martin Nguyen, (unknown), David W. Cescon	3
7	Oral self-management of palbociclib using mobile technology: Findings from a nurse-led randomized controlled trial 2024 ·Asia-Pacific Journal of Oncology Nursing ·(unknown), Margaret Barton‐Burke, (unknown), (unknown), Zhigang Zhang, Andrea Smith, Mark E. Robson	1
8	Immunotherapy related patient-reported outcomes from five randomized controlled trials in patients with triple negative breast cancer: A systematic review. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Larry Norton, Mark E. Robson, Wanqing Iris Zhi	0
9	Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer 2024 ·Cancer Research ·Emanuela Ferraro, Atif J. Khan, George Plitas, Yuan Chen, (unknown), (unknown), Chau T. Dang, Mark E. Robson, Sarat Chandarlapaty, Shanu Modi, Pedram Razavi, Sherry Shen	1
10	Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach. 2024 ·Journal of Clinical Oncology ·Enrico Moiso, Emanuela Ferraro, Luc Cabel, Anton Safonov, (unknown), (unknown), Komal Jhaveri, Larry Norton, Mark E. Robson, Shanu Modi, Sarat Chandarlapaty, Pedram Razavi	1
11	TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. 2024 ·Journal of Clinical Oncology ·Nadine Tung, Mark E. Robson, Rita Nanda, Tianyu Li, Shaveta Vinayak, Payal D. Shah, Katia Khoury, Gretchen Kimmick, Cesar Augusto Santa-Maria, Adam Brufsky, Michelle K. DeMeo, (unknown), Lisa A. Carey, Gerburg M. Wulf, Susan M. Domchek, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Judy E. Garber	8
12	419P Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution 2023 ·Annals of Oncology ·(unknown), Maximilian Klar, Nour Abuhadra, Mark E. Robson, Joshua Z. Drago	1
13	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model 2021 ·JCO Precision Oncology ·Shannon Gallagher, Elisha Hughes, Allison W. Kurian, Susan M. Domchek, Judy E. Garber, (unknown), Brian Morris, (unknown), Stephanie Meek, Eric T. Rosenthal, Benjamin B. Roa, Thomas P. Slavin, Susanne Wagner, Jeffrey N. Weitzel, Alexander Gutin, Jerry S. Lanchbury, Mark E. Robson	14
14	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) 2018 ·Clinical Cancer Research ·Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva‐Maria Grischke, Lida A. Mina, Judith Balmañà, Peter A. Fasching, Sara A. Hurvitz, Andrew Wardley, Colombe Chappey, Alison L. Hannah, Mark E. Robson	88
15	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation breakdown → 2017 ·New England Journal of Medicine ·Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, Pierfranco Conté	2156
16	An ethnographic study of the introduction of internal supervisors to an internal coaching scheme 2016 ·SHILAP Revista de lepidopterología ·Mark E. Robson	1
17	Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report 2010 ·Clinical Cancer Research ·Nicolas Girard, Emil Lou, Christopher G. Azzoli, (unknown), Mark E. Robson, (unknown), Irene Orlow, Yasushi Yatabe, Khédoudja Nafa, Marc Ladanyi, Agnès Viale, Mark G. Kris, Gregory J. Riely, Vincent A. Miller, Robert J. Klein, Keitaro Matsuo, William Pao	70
18	The 6q22.33 Locus and Breast Cancer Susceptibility 2009 ·Cancer Epidemiology Biomarkers & Prevention ·Tomas Kirchhoff, Zhang-qun Chen, Bert Gold, Prodipto Pal, Mia M. Gaudet, Kristi Kosarin, Douglas A. Levine, Peter K. Gregersen, (unknown), (unknown), Mark E. Robson, Robert J. Klein, Clifford A. Hudis, Larry Norton, Michael Dean, Kenneth Offit	15
19	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study 2008 ·Journal of Clinical Oncology ·Noah D. Kauff, Susan M. Domchek, Tara M. Friebel, Mark E. Robson, Johanna Lee, Judy E. Garber, Claudine Isaacs, D. Gareth Evans, Henry T. Lynch, Rosalind A. Eeles, Susan L. Neuhausen, Mary B. Daly, Ellen Matloff, Joanne L. Blum, Paul Sabbatini, Richard R. Barakat, Clifford A. Hudis, Larry Norton, Kenneth Offit, Timothy R. Rebbeck	381
20	Prevalence of Recurring BRCA Mutations Among Ashkenazi Jewish Women with Breast Cancer 1997 ·Genetic Testing ·Mark E. Robson, (unknown), (unknown), (unknown), Murray H. Seltzer, Teresa Gilewski, Bruce R. Haas, Michael Osborne, Larry Norton, Fiona J. Gilbert, Kenneth Offit	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact